Indaptus Therapeutics is trading 6.1% higher at $2.52 on October 9, 2026, with no fresh company-specific announcement identified to explain the move. - Surfaced coverage mainly referenced previously disclosed financing and resale filings, rather than a new catalyst. - Biotech is down 2.04%, while major indices are modestly higher; neither clearly explains the gain. - Current volume data was unavailable, and the reason for the move remains unclear.